Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

NNC4004-0002 · NNC4004

Other · developed by Novo Nordisk

Phase 1 Most advanced trial
NVO Developer
1 Registered trials

What is NNC4004-0002?

NNC4004-0002 is an agent given subcutaneously, studied as a single ascending dose in healthy volunteers and in hyperuricemia.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
NNC4004
Drug type
Other
Therapy area
Metabolic
Developer
Novo Nordisk A/S (NVO)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06859073 Phase 1 Healthy Volunteers Active not recruiting NVO

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Healthy VolunteersHyperuricemia

More from Novo Nordisk

Sources

Updated Nov 8, 2026. Something wrong or missing? Report it on the NVO page.

Follow NVO, the company behind NNC4004-0002

See NVO's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

NVO catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.